Chen Qun, Yuan Hao, Shi Guo-Dong, Wu Yang, Liu Dong-Fang, Lin Yu-Ting, Chen Lei, Ge Wan-Li, Jiang Kuirong, Miao Yi
Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Pancreas Institute, Nanjing Medical University, Nanjing, China.
Onco Targets Ther. 2018 May 9;11:2709-2723. doi: 10.2147/OTT.S157759. eCollection 2018.
Previous studies have reported that nuclear receptor subfamily 5, group A, member 2 (NR5A2) polymorphisms (rs3790843 G>A, rs3790844 T>C, rs12029406 C>T) are associated with the risk of pancreatic cancer. However, the results of epidemiological investigations are still controversial. In order to explore its potential attributing factors, we pooled the updated literatures to evaluate the association between NR5A2 polymorphism and the risk of pancreatic cancer in this meta-analysis.
Databases such as PubMed, Google Scholar and China National Knowledge Infrastructure were searched for eligible articles following strict inclusion and exclusion criteria (updated to November 18, 2017). Odds ratios (ORs) and 95% CIs were computed to assess the intensity of association. In addition, heterogeneity, sensitivity analysis and publication bias were explored. All statistical analyses were conducted by STATA 14.0.
Our results showed that the rs3790843 (GA vs GG: OR=0.86, CI=0.76-0.98, =0.992; GA+AA vs GG: OR=0.83, CI=0.73-0.94, =0.950; A vs G: OR=0.85, CI=0.78-0.93, =0.802), rs3790844 (CC vs TT: OR=0.65, CI=0.54-0.78, =0.617; CC vs TT+CT: OR=0.73, CI=0.62-0.85, =0.742; C vs T: OR=0.78, CI=0.73-0.84, =0.555) and rs12029406 (TT vs CC: OR=0.73, CI=0.61-0.89, =0.483; TT vs CC+CT: OR=0.78, CI=0.66-0.92, =0.648; T vs C: OR=0.87, CI=0.79-0.95, =0.837) polymorphisms were associated statistically with the risk of pancreatic cancer. Furthermore, the results of subgroup analysis showed that rs3790843 and rs3790844 polymorphisms were especially related to the risk of pancreatic cancer in Caucasian population.
Our results revealed that NR5A2 may have a protective effect on pancreatic cancer. However, more well-designed researches are needed to verify the relationship between NR5A2 polymorphisms and the risk of pancreatic cancer.
既往研究报道,核受体亚家族5 A组成员2(NR5A2)基因多态性(rs3790843 G>A、rs3790844 T>C、rs12029406 C>T)与胰腺癌风险相关。然而,流行病学调查结果仍存在争议。为探究其潜在影响因素,我们汇总最新文献,在本荟萃分析中评估NR5A2基因多态性与胰腺癌风险的关联。
按照严格的纳入和排除标准(更新至2017年11月18日),检索PubMed、谷歌学术和中国知网等数据库中的相关文章。计算比值比(OR)和95%可信区间(CI)以评估关联强度。此外,还进行了异质性、敏感性分析和发表偏倚分析。所有统计分析均使用STATA 14.0软件完成。
我们的结果显示,rs3790843(GA vs GG:OR=0.86,CI=0.76 - 0.98,P=0.992;GA+AA vs GG:OR=0.83,CI=0.73 - 0.94,P=0.950;A vs G:OR=0.85,CI=0.78 - 0.93,P=0.802)、rs3790844(CC vs TT:OR=0.65,CI=0.54 - 0. 78,P=0.617;CC vs TT+CT:OR=0.73,CI=0.62 - 0.85,P=0.742;C vs T:OR=0.78,CI=0.73 - 0.84,P=0.555)和rs12029406(TT vs CC:OR=0.73,CI=0.61 - 0.89,P=0.483;TT vs CC+CT:OR=0.78,CI=0.66 - 0.92,P=0.648;T vs C:OR=0.87,CI=0.79 - 0.95,P=0.837)基因多态性与胰腺癌风险存在统计学关联。此外,亚组分析结果显示,rs3790843和rs3790844基因多态性与白种人群的胰腺癌风险尤其相关。
我们的结果表明,NR5A2可能对胰腺癌具有保护作用。然而,需要更多设计良好的研究来验证NR5A2基因多态性与胰腺癌风险之间的关系。